SG11202000055PA - Antibodies that modulate a biological activity expressed by a cell - Google Patents
Antibodies that modulate a biological activity expressed by a cellInfo
- Publication number
- SG11202000055PA SG11202000055PA SG11202000055PA SG11202000055PA SG11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA SG 11202000055P A SG11202000055P A SG 11202000055PA
- Authority
- SG
- Singapore
- Prior art keywords
- utrecht
- yalelaan
- international
- cell
- bind
- Prior art date
Links
- 230000004071 biological effect Effects 0.000 title abstract 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 abstract 4
- 102000017578 LAG3 Human genes 0.000 abstract 4
- 210000004027 cell Anatomy 0.000 abstract 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 abstract 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17180070 | 2017-07-06 | ||
| PCT/NL2018/050451 WO2019009728A1 (en) | 2017-07-06 | 2018-07-06 | ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000055PA true SG11202000055PA (en) | 2020-02-27 |
Family
ID=59295099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000055PA SG11202000055PA (en) | 2017-07-06 | 2018-07-06 | Antibodies that modulate a biological activity expressed by a cell |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11732043B2 (he) |
| EP (1) | EP3649156A1 (he) |
| JP (1) | JP2020525533A (he) |
| KR (1) | KR20200037250A (he) |
| CN (3) | CN118027197A (he) |
| AU (1) | AU2018297061B2 (he) |
| BR (1) | BR112020000228A2 (he) |
| CA (1) | CA3068933A1 (he) |
| EA (1) | EA202090005A1 (he) |
| IL (1) | IL271833B1 (he) |
| PH (1) | PH12020550010A1 (he) |
| SG (1) | SG11202000055PA (he) |
| TW (1) | TW201920275A (he) |
| WO (1) | WO2019009728A1 (he) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10844119B2 (en) | 2016-10-11 | 2020-11-24 | Agenus Inc. | Anti-LAG-3 antibodies and methods of use thereof |
| EP3565842A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| GB201802573D0 (en) * | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| US20210115138A1 (en) * | 2018-03-20 | 2021-04-22 | WuXi Biologics Ireland Limited | Novel bispecific pd-1/lag-3 antibody molecules |
| TW202003569A (zh) * | 2018-03-30 | 2020-01-16 | 荷蘭商美勒斯公司 | 多價抗體 |
| JP2022530496A (ja) * | 2019-04-26 | 2022-06-29 | ウーシー バイオロジクス アイルランド リミテッド | Ｐｄ－１およびｌａｇ－３に対する二重特異性抗体 |
| AR118898A1 (es) | 2019-05-09 | 2021-11-10 | Merus Nv | Dominios variantes para multimerizar proteínas y su separación |
| WO2021242876A1 (en) * | 2020-05-27 | 2021-12-02 | Agilent Technologies, Inc. | Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc) |
| CN113416249B (zh) * | 2020-10-21 | 2023-04-07 | 北京智仁美博生物科技有限公司 | 针对破伤风毒素的组合物 |
| EP4019633A1 (en) * | 2020-12-23 | 2022-06-29 | Technische Universität München | Conditional cell connectors |
| TW202302630A (zh) | 2021-03-31 | 2023-01-16 | 荷蘭商美勒斯公司 | 新穎多特異性抗體 |
| US11993654B2 (en) | 2021-03-31 | 2024-05-28 | Merus N.V. | PD-1 binding domains |
| BR112023019703A2 (pt) | 2021-03-31 | 2023-10-31 | Incyte Corp | Frações de ligação multiespecíficas compreendendo novos domínios de ligação à pd-1 |
| WO2024072893A1 (en) * | 2022-09-28 | 2024-04-04 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| CA2965865C (en) | 2002-07-18 | 2021-10-19 | Merus N.V. | Recombinant production of mixtures of antibodies |
| WO2018157954A1 (de) | 2017-03-01 | 2018-09-07 | Fluorchemie Gmbh Frankfurt | Neuartiges material, sowie dessen herstellung zur anwendung als speichermedium im sensitiven energiespeichersystem im niederen, mittleren und hochtemperaturbereich |
| JP4361545B2 (ja) | 2005-05-09 | 2009-11-11 | 小野薬品工業株式会社 | ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 |
| BRPI0911652A2 (pt) | 2008-04-11 | 2015-08-04 | Merrimack Pharmaceuticals Inc | Ligantes de albumina sérica humana e seus conjugados |
| WO2009157771A2 (en) | 2008-06-27 | 2009-12-30 | Merus B.V. | Antibody producing non-human mammals |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| JP2012501670A (ja) | 2008-09-12 | 2012-01-26 | アイシス・イノベーション・リミテッド | Ｐｄ−１特異抗体およびその使用 |
| PT2699264T (pt) | 2011-04-20 | 2018-05-23 | Medimmune Llc | Anticorpos e outras moléculas que ligam b7-h1 e pd-1 |
| US9701749B2 (en) | 2011-08-11 | 2017-07-11 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for autoimmune diseases comprising PD-1 agonist |
| SG10201607369QA (en) | 2012-04-20 | 2016-10-28 | Merus Nv | Methods and means for the production of ig-like molecules |
| HUE042040T2 (hu) | 2012-09-27 | 2019-06-28 | Merus Nv | Bispecifikus IGG antitestek mint T-sejt kapcsolók |
| UY36032A (es) * | 2014-03-14 | 2015-10-30 | Novartis Ag | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas |
| TWI693232B (zh) * | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| WO2016011069A1 (en) | 2014-07-15 | 2016-01-21 | The Board Of Trustees Of The Leland Stanford Junior University | Medical uses of cd38 agonists (antibodies) |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| CN108337890B (zh) * | 2015-06-23 | 2021-10-15 | 纪念斯隆-凯特琳癌症中心 | 新型pd-1免疫调节剂 |
| SI3328419T1 (sl) * | 2015-07-30 | 2021-11-30 | Macrogenics, Inc. | PD-1-vezavne molekule in postopki uporabe le-teh |
| WO2017024515A1 (en) * | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| US11124569B2 (en) | 2015-09-18 | 2021-09-21 | Dana-Farber Cancer Institute, Inc. | Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors |
| TWI756187B (zh) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| WO2017069628A2 (en) * | 2015-10-23 | 2017-04-27 | Merus N.V. | Binding molecules that inhibit cancer growth |
| UA121914C2 (uk) * | 2015-11-18 | 2020-08-10 | Мерк Шарп І Доум Корп. | Молекула, що зв'язує pd1 і lag3 |
| MX2019002867A (es) | 2016-09-19 | 2019-11-12 | Celgene Corp | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. |
| US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
| EA201990578A1 (ru) * | 2016-09-23 | 2019-10-31 | Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой | |
| EP3389702A4 (en) * | 2017-02-22 | 2019-08-14 | I-Mab | ANTI-LAG-3 ANTIBODIES AND USES THEREOF |
| DE102017107951A1 (de) | 2017-03-03 | 2018-09-06 | Sarah Yanik | Zusammensetzung, insbesondere für die Behandlung von Huf- und Klauenerkrankungen bei Tieren, und deren Herstellung |
| WO2019009726A1 (en) * | 2017-07-06 | 2019-01-10 | Merus N.V. | BINDING MOLECULES FOR MODULATING THE BIOLOGICAL ACTIVITY EXPRESSED BY A CELL |
| MX2020000055A (es) * | 2017-07-06 | 2020-08-06 | Merus Nv | Anticuerpos biespecificos antiproteina 1 de muerte celular programada (pd-1) -anti inmunoglobulina de celulas t y dominio de mucina que contiene -3 (tim-3). |
| MA54943A (fr) * | 2019-02-14 | 2021-12-22 | Merus Nv | Production de compositions comprenant deux anticorps ou plus |
| JP2023528002A (ja) | 2020-05-27 | 2023-07-03 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｔ細胞を選択的に調節するための二重特異性分子 |
-
2018
- 2018-07-06 US US16/628,939 patent/US11732043B2/en active Active
- 2018-07-06 CA CA3068933A patent/CA3068933A1/en active Pending
- 2018-07-06 JP JP2020500187A patent/JP2020525533A/ja active Pending
- 2018-07-06 AU AU2018297061A patent/AU2018297061B2/en active Active
- 2018-07-06 IL IL271833A patent/IL271833B1/he unknown
- 2018-07-06 SG SG11202000055PA patent/SG11202000055PA/en unknown
- 2018-07-06 CN CN202311681635.8A patent/CN118027197A/zh active Pending
- 2018-07-06 CN CN202311670530.2A patent/CN117964759A/zh active Pending
- 2018-07-06 WO PCT/NL2018/050451 patent/WO2019009728A1/en unknown
- 2018-07-06 CN CN201880057358.4A patent/CN111094350A/zh active Pending
- 2018-07-06 KR KR1020207003657A patent/KR20200037250A/ko not_active Application Discontinuation
- 2018-07-06 EA EA202090005A patent/EA202090005A1/ru unknown
- 2018-07-06 EP EP18749181.6A patent/EP3649156A1/en active Pending
- 2018-07-06 TW TW107123603A patent/TW201920275A/zh unknown
- 2018-07-06 BR BR112020000228-3A patent/BR112020000228A2/pt unknown
-
2020
- 2020-01-06 PH PH12020550010A patent/PH12020550010A1/en unknown
-
2023
- 2023-04-27 US US18/308,232 patent/US20230406932A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11732043B2 (en) | 2023-08-22 |
| BR112020000228A2 (pt) | 2020-07-14 |
| JP2020525533A (ja) | 2020-08-27 |
| AU2018297061A1 (en) | 2020-01-30 |
| US20230406932A1 (en) | 2023-12-21 |
| KR20200037250A (ko) | 2020-04-08 |
| TW201920275A (zh) | 2019-06-01 |
| AU2018297061B2 (en) | 2021-05-06 |
| CN117964759A (zh) | 2024-05-03 |
| CN118027197A (zh) | 2024-05-14 |
| US20200216540A1 (en) | 2020-07-09 |
| WO2019009728A8 (en) | 2020-01-09 |
| WO2019009728A1 (en) | 2019-01-10 |
| EA202090005A1 (ru) | 2020-06-18 |
| IL271833A (he) | 2020-02-27 |
| CA3068933A1 (en) | 2019-01-10 |
| PH12020550010A1 (en) | 2020-10-12 |
| EP3649156A1 (en) | 2020-05-13 |
| CN111094350A (zh) | 2020-05-01 |
| IL271833B1 (he) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202000055PA (en) | Antibodies that modulate a biological activity expressed by a cell | |
| SG11201809669RA (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201901899PA (en) | Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201811184UA (en) | Lag -3 binding members | |
| SG11201908088RA (en) | Antibodies against pd-l1 | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201805870YA (en) | Bispecific t cell engaging antibody constructs | |
| SG11201807474SA (en) | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201803834UA (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| SG11201907364WA (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof |